Investor Type | Firm |
Industries | IT (& TMT) • BioTech • Businesses Solutions • HealthTech (& Fitness) • Medical Devices (& Hospital Services) • Life Science • Oncology |
Investing | United States |
Investment Range | $25,000,000 - $25,000,000 |
Revelation Partners specializes in providing flexible capital solutions to healthcare companies, focusing primarily on secondary transactions in the life science space. They offer liquidity to existing shareholders and supply growth capital, strategically partnering with management teams to scale businesses. With an investment range up to $25 million, they target IT, BioTech, Business Solutions, HealthTech, Medical Devices, Life Sciences, and Oncology sectors. Since being founded in 2013 in San Francisco, California, Revelation Partners has cultivated a significant portfolio and expertise in the healthcare sector. They manage over $1.5 billion in assets and have more than 50 active portfolio companies, having also seen the total value of exited companies surpass $100 billion. Their investment approach includes creating customized liquidity solutions for founders, early employees, investors, and corporate shareholders of privately-held healthcare firms. Recognizing the different time horizons of various shareholders, they aim to align interests and provide tailored solutions such as founder liquidity, fund restructurings, continuation funds, as well as direct share purchases. Their flexibility also extends to partnership with general partners (GPs) to offer liquidity resolutions to limited partners (LPs) in a variety of transactions. Revelation Partners is proud of their responsive, problem-solving nature and emphasizes creating solutions that maximize outcomes for all parties involved. Key transactions showcase their capacity to provide immediate liquidity, reserves for follow-on financings, and ongoing strategic partnerships, including board of directors roles. They have also demonstrated an ability to participate in primary financing rounds to further companies' growth, exemplified by their strategic capital partnerships that support the scaling and commercializing of breakthrough healthcare technologies.